Related Experiment Video
Updated: Jun 23, 2026
11:07
Biochemical Reconstitution of Steroid Receptor•Hsp90 Protein Complexes and Reactivation of Ligand Binding
Published on: September 21, 2011
How post-translational modifications impact glucocorticoid receptor function in human pathologies.
Zélie Bouveret1,2,3, Ludivine Pruvost1,2,3, Olivier Trédan1,2,3,4
1Université Claude Bernard Lyon 1, Lyon, 69000, France.
Cell Communication and Signaling : CCS
|June 20, 2026
Summary
Glucocorticoid receptor (GR) post-translational modifications (PTMs) regulate essential cellular functions and are implicated in diseases like cancer and Alzheimer's. Understanding these PTMs and their regulators offers promising therapeutic targets.
Area of Science:
- Endocrinology
- Molecular Biology
- Cellular Biology
Background:
- Glucocorticoid receptor (GR) is a nuclear hormone receptor crucial for regulating inflammation, immunity, and metabolism.
- Glucocorticoids (GCs) are widely prescribed drugs, highlighting the importance of GR signaling in various diseases.
- GR activity is modulated by post-translational modifications (PTMs), which influence its function and localization.
Purpose of the Study:
- To provide an integrated overview of current knowledge on GR PTMs.
- To highlight the mechanistic insights and disease relevance of GR PTMs.
- To identify enzymes and readers of GR PTMs as potential therapeutic targets.
Main Methods:
- Literature review of GR post-translational modifications.
- Analysis of GR PTMs in the context of disease pathogenesis.
- Identification of enzymes and protein interactors involved in GR PTMs.
Main Results:
- GR PTMs, beyond phosphorylation, significantly impact GR function, localization, and stability.
- Aberrant GR PTMs are linked to prevalent diseases including cancer, chronic inflammatory conditions, and neurological disorders like Alzheimer's disease.
- Specific enzymes and PTM readers involved in GR regulation represent promising targets for therapeutic intervention.
Conclusions:
- Post-translational modifications play a critical role in fine-tuning Glucocorticoid Receptor activity.
- Dysregulation of GR PTMs contributes to the pathophysiology of numerous widespread diseases.
- Targeting the enzymes and readers of GR PTMs holds significant therapeutic potential for treating GR-associated pathologies.
Related Concept Videos
02:04Covalently Linked Protein Regulators
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
These groups modify specific amino acids in a protein.
01:19Cushing Syndrome II: Pathophysiology
Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
01:12GPCR Desensitization
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
01:09GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...